Nexthera Capital

Latest statistics and disclosures from Nexthera Capital's latest quarterly 13F-HR filing:

Tip: Access up to 7 years of quarterly data

Positions held by Nexthera Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Nexthera Capital

Nexthera Capital holds 23 positions in its portfolio as reported in the June 2019 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Intercept Pharmaceuticals In 10.1 $12M +1175% 152k 79.57
 View chart
Insmed (INSM) 10.0 $12M +65% 471k 25.60
 View chart
Audentes Therapeutics 9.3 $11M +17% 294k 37.86
 View chart
Neurocrine Biosciences (NBIX) 6.5 $7.8M +284% 92k 84.43
 View chart
Sarepta Therapeutics (SRPT) 6.4 $7.6M +136% 50k 151.96
 View chart
Global Blood Therapeutics In 6.2 $7.5M +63% 142k 52.60
 View chart
Immunomedics 6.0 $7.3M +56% 524k 13.87
 View chart
Coherus Biosciences (CHRS) 5.8 $7.0M NEW 316k 22.10
 View chart
Ascendis Pharma A S (ASND) 5.8 $6.9M NEW 60k 115.16
 View chart
Pacira Pharmaceuticals (PCRX) 5.4 $6.5M NEW 149k 43.49
 View chart
Urogen Pharma (URGN) 5.3 $6.4M +33% 177k 35.94
 View chart
Uniqure Nv (QURE) 3.9 $4.7M +54% 60k 78.15
 View chart
Amarin Corporation (AMRN) 3.7 $4.5M +54% 230k 19.39
 View chart
Abbvie (ABBV) 3.2 $3.8M NEW 53k 72.72
 View chart
Biohaven Pharmaceutical Holding 3.1 $3.8M NEW 86k 43.79
 View chart
Mylan Nv 1.6 $2.0M NEW 103k 19.04
 View chart
Intra Cellular Therapies (ITCI) 1.6 $1.9M NEW 144k 12.98
 View chart
Regeneron Pharmaceuticals (REGN) 1.5 $1.8M NEW 5.7k 312.99
 View chart
Madrigal Pharmaceuticals (MDGL) 1.4 $1.6M +346% 15k 104.78
 View chart
Dermira 1.1 $1.3M NEW 138k 9.56
 View chart
Gilead Sciences (GILD) 1.1 $1.3M NEW 19k 67.55
 View chart
Anaptysbio Inc Common (ANAB) 0.6 $679k NEW 12k 56.46
 View chart
Allergan 0.5 $560k -75% 3.3k 167.31
 View chart

Past Filings by Nexthera Capital

SEC 13F filings are viewable for Nexthera Capital going back to 2015